Results 81 to 90 of about 406,491 (336)

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. [PDF]

PLoS ONE, 2012
A major challenge in breast cancer therapy is the lack of an effective therapeutic option for a particularly aggressive subtype of breast cancer, triple-negative breast cancer.
Yanfeng Qi, Xueqi Fu, Zhenggang Xiong, Haitao Zhang, Steven M Hill, Brian G Rowan, Yan Dong   +6 more
doaj   +1 more source

Breast cancer receptor status assessment and clinicopathological association in Nigerian women: A retrospective analysis [PDF]

, 2014
Background: Breast cancer markers are becoming increasingly important in breast cancer research due to their impact on prognosis, treatment and survival.
Ayodele, Sanni D., Javid, Farideh A., Makanjuola, Samira B.L., Obafunwa, John O., Oludara, Mobolaji A, Popoola, Abiodun O.   +5 more
core   +1 more source

Imaging of triple-negative breast cancer

Annals of Oncology, 2012
Although triple-negative breast cancer (TNBC) has been studied extensively in the oncology and pathology literature, there are few reports on imaging features. Emerging data suggest that imaging features of TNBC are substantially different from other primary breast cancer immunotypes. In this work, we reviewed multi-modality imaging features of primary
B E, Dogan, L W, Turnbull
openaire   +2 more sources

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Journal of the National Cancer Institute, 2021
Background Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple ...
L. Emens, L. Molinero, S. Loi, H. Rugo, A. Schneeweiss, V. Diéras, H. Iwata, C. Barrios, M. Nechaeva, Anh Nguyen-Duc, S. Chui, A. Husain, E. Winer, S. Adams, P. Schmid   +14 more
semanticscholar   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy [PDF]

, 2012
Triple-negative breast cancers lack estrogen receptor α (ERα), progesterone receptor, and do not overexpress human epidermal growth factor receptor 2 (Her-2).
Carsten Gründker, Günter Emons, Rainer Girgert   +2 more
core   +1 more source

A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging

Cell, 2018
The immune system is critical in modulating cancer progression, but knowledge of immune composition, phenotype, and interactions with tumor is limited. We used Multiplexed Ion Beam Imaging by Time-of-Flight (MIBI-TOF) to simultaneously quantify in-situ ...
Leeat Keren, M. Bosse, Diana Marquez, Roshan Angoshtari, Samir Jain, S. Varma, Soo-Ryum Yang, A. Kurian, D. V. Valen, Robert West, S. Bendall, Michael Angelo   +11 more
semanticscholar   +1 more source

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer

Cell Research, 2022
Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of metabolites in triple-negative breast cancer (TNBC) are still lacking.
Yi Xiao, D. Ma, Yun-Song Yang, Fan Yang, Jianlong Ding, Y. Gong, Linbailu Jiang, Li-Ping Ge, Songyang Wu, Qiang Z. Yu, Qing Zhang, F. Bertucci, Qiuzhuang Sun, Xin Hu, Da-Qiang Li, Z. Shao, Yizhou Jiang   +16 more
semanticscholar   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source